<DOC>
	<DOC>NCT01691794</DOC>
	<brief_summary>The purpose of this study is to collect safety clinical data in HIV-infected pediatric patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are receiving atazanavir capsule boosted with ritonavir and an optimized nucleoside reverse transcriptase inhibitor backbone therapy as part of their antiretroviral regimen.</brief_summary>
	<brief_title>Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<criteria>Confirmed HIV1 infection diagnosed by protocol criteria Male or female children, ≥ 6 years to &lt;17 years 6 months of age at the time of first treatment Antiretroviralnaïve or treatmentexperienced participants with a detectable viral load Antiretroviralnaïve participants must have genotypic sensitivity at screening to atazanavir and at least 2 nucleoside reverse transcriptase inhibitors (NRTIs), which have been approved for pediatric use and dosed per local country label Antiretroviralexperienced participants must have documented genotypic and phenotypic sensitivity at screening to atazanavir (fold change in susceptibility &lt;2.2) and at least 2 NRTIs, which have been approved for pediatric use and dosed per local country label. Experienced participants who received atazanavir with or without ritonavir at any time prior to study enrollment Antiretroviralnaive or experienced HIV1 infected patients with contraindication to study medications Documented cardiac conduction abnormality, significant cardiac dysfunction, or a history syncope Family history of QTc interval syndrome, Brugada syndrome, right ventricular dysplasia, or a corrected QTc interval of &gt;440 ms at screening One of the following cardiac rhythm abnormalities documented on the screening electrocardiogram: 1. First degree atrioventricular (AV) block, as defined by protocol 2. Type I second degree AV block while awake, type II second degree AV block at any time, complete AV block at any time, or ageadjusted heart rate &lt;2nd percentile Coinfection with either hepatitis B or C virus</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>